|MINI SYMPOSIUM: HEAD AND NECK
|Year : 2012 | Volume
| Issue : 1 | Page : 27-32
p53 immunoprofiling of potentially malignant oral disorders: A case series analysis
VM Reddy1, A Kamath2, RA Radhakrishnan3
1 Department of Oral Pathology, S Nijalingappa Institute of Dental Sciences and Research, Gulbarga, India
2 Department of Community Medicine, Kasturba Medical College, Manipal, India
3 Department of Oral Pathology, Manipal College of Dental Sciences, Manipal University, Manipal, India
|Date of Web Publication||25-Jul-2012|
R A Radhakrishnan
Department of Oral Pathology, Manipal College of Dental Sciences, Manipal University, Manipal
Source of Support: Manipal University, Conflict of Interest: None
Context: p53 tumor suppressor gene which is a frequent target for mutations in a high percentage of oral cancer is regarded as an early event in carcinogenesis. Aim: The role of p53 was assessed in potentially malignant oral disorders (PMOD) to ascertain its prognostic significance. Settings and Design: Retrospective case series analysis was carried out on 30 paraffin-embedded tissue blocks of confirmed oral leukoplakia with dysplasia. Materials and Methods: 10 cases of each of mild, moderate, and severe dysplasia were immunohistochemically analyzed for p53 expression. The intensity of staining, intracellular localization, and basal and/or suprabasal distribution were assessed. Statistics: The intensity of p53 staining and its distribution were analyzed by the Chi-square test. The intracellular localization of p53 in different grades of dysplasia was subjected to one way ANOVA. P<0.05 was considered significant. Results: 21/30 cases of epithelial dysplasia were positive for p53 immunopositivity. Intensity of p53 expression was strong in 12 cases and weak in 9 cases (P<0.05). p53 positivity was confined to basal cells in mild dysplasia, while severe dysplasia showed both basal and suprabasal staining (P<0.05). Nuclear and cytoplasmic staining between and within the groups were F=9.027 and F=6.465 respectively with high significance noted between mild dysplasia and severe dysplasia. Conclusions: Increased p53 expressivity and greater cellular localization with increase in the severity of dysplasia indicated a direct association between the degree of epithelial dysplasia and p53 accretion, which occurs as an early event in oral carcinogenesis.
Keywords: Epithelial dysplasia, Immunohistochemistry, leukoplakia, oral cancer, p53, potentially malignant oral disorders
|How to cite this article:|
Reddy V M, Kamath A, Radhakrishnan R A. p53 immunoprofiling of potentially malignant oral disorders: A case series analysis. Indian J Cancer 2012;49:27-32
|How to cite this URL:|
Reddy V M, Kamath A, Radhakrishnan R A. p53 immunoprofiling of potentially malignant oral disorders: A case series analysis. Indian J Cancer [serial online] 2012 [cited 2020 Jun 4];49:27-32. Available from: http://www.indianjcancer.com/text.asp?2012/49/1/27/98913
| » Introduction|| |
Oral cancers may be preceded by clinically evident potentially malignant oral disorders (PMOD) among which leukoplakia is the most common , with malignant transformation rate ranging from 0.6% to 18%.  This may be directly related to the severity of dysplasia as it ranges from 5% for leukoplakia with mild dysplasia to 43% for leukoplakia with severe dysplasia.  Thus, the transformation rate of leukoplakia to oral cancer is based on the microscopic assessment of dysplasia and the degree to which it occurs. ,, However, such an assessment is arbitrary, weighed down by great inter and intra-examiner variability. , Neoplastic process in PMOD has been assessed by DNA aneuploidy, loss of heterozygosity, mutations, and aberrant expression of genes.  Although, the tools for assessing these markers have shown promise in determining the risk of cancer, their use has been hampered by technical difficulties, making their wide-scale application challenging. In addition, some markers have proved to be of limited predictive value, thus necessitating validation of proven markers for risk assessment.
One such marker is the p53 tumor suppressor gene which is a frequent target for mutations in a high percentage of tumors and is regarded as an early event in carcinogenesis. It is involved in cell cycle control, apoptosis, and the preservation of genomic stability.  The mutant form of p53 protein is stable, has an extended half life, and can be detected by immunohistochemistry. This mutant form has been expressed in a high percentage of tumors including breast, lung, and colon cancers.  In our study, we aim to assess the role of p53 expression by immunohistochemistry in oral leukoplakia with different histological grades of epithelial dysplasia. We hypothesized that p53 immunostaining is important in ascertaining the prognostic significance of PMOD in particular oral leukoplakia with increasing degree of dysplasia.
| » Materials and Methods|| |
A purposive sampling of 30 formalin fixed paraffin embedded tissue blocks of oral leukoplakia with histological confirmation of epithelial dysplasia was retrieved from the department΄s archives. These cases were further segregated into 10 cases of each of mild, moderate, and severe dysplasia, by routine H and E staining applying criteria put forth by Lumerman
et al. 1995.  Identical tissue sections from each of the 30 cases were immunohistochemically analyzed for p53 expression using monoclonal antibody. Tissue sections of breast cancer and oral squamous cell carcinoma, which show strongly positive expression for p53, were used as positive controls. 10 normal oral mucosal tissue sections obtained from buccal mucosa were used for comparison with dysplastic epithelium.
5 μm sections were placed over 3-aminopropyl triethoxy silane (APES)-coated slides (Sigma Aldrich Chemical Co., St. Louis, MO, USA) and dewaxed through three changes of xylene and hydrated through descending grades of alcohol. Sections were dipped in freshly prepared 3% H 2 O 2 in methanol for 20 min to block endogenous peroxidase activity. For antigen retrieval, sections were immersed in preheated 0.01 mM sodium citrate buffer and boiled for 12 min in a 5 L stainless steel pressure cooker. Following non-specific antigen blocking, the sections were incubated with the prediluted primary antibody (clone DO7; Dako Glostrup, Denmark) at 37°C for 60 min in a humid chamber. The sections were then incubated with the biotinylated secondary antibody (Fc conjugated Goat-antimouse IgG, Sigma Aldrich Chemical Co., St. Louis, MO, USA) diluted 1:200, at room temperature for 30 min. The sections were incubated with a streptavidin-peroxidase conjugate (Sigma Aldrich Chemical Co., St. Louis, MO, USA) diluted at a concentration of 1:200 for 30 min. Between each step, the sections were washed thoroughly for 5 min in two changes of PBS with 0.1% Tween 20. For visualization, the sections were incubated with DAB (Diaminobenzidine tetrahydrochloride, Dako cytomation, Denmark) at a concentration of 1:50 for 5 min. The sections were then counterstained using Mayer's haematoxylin for 45 seconds and washed gently in running tap water for 2 min.
The presence of brown precipitate in the nucleus, cytoplasm, or both in the epithelial cells indicated p53-positive expression. Assessment of p53 expression was performed using a light microscope at x40 and x100 magnifications. In each of the positive tissue sections, the number of p53-positive cells, the intensity of p53 expression, pattern of staining in terms of its intracellular localization was assessed as well as its basal and supra basal distribution.
Each of the histological grades of dysplasia were evaluated for intensity of p53 expression and graded as negative (-), when there was no nuclear staining in any cell; weak (+), when the nuclear staining was in less than 25% cells and strong (++), when the nuclear staining was in more than 50%) cells.  The distribution of p53-positive cells in epithelium were assessed as basal or both basal and suprabasal.  The intracellular localization of p53 with reference to its nuclear or cytoplasmic staining was evaluated. For assessing the intracellular localization of p53 staining, 100 randomly selected cells were studied under a 100× objective. To eliminate subjective bias, two observers independently evaluated the values and its mean was subjected to further statistical analysis.
Statistical analysis was performed using SPSS 13.0 software. The grading carried out by two independent observers was statistically analyzed using the Mann-Whitney U-test to check for inter observer variability. For analysis of p53 immunostaining, two observers independently evaluated the intensity and pattern of distribution and the mean values were subjected for further statistical analysis. The intensity of staining and p53 distribution in the epithelium was compared using the chi square "χ2" test and the likelihood ratio. P<0.05 was considered significant. The reliability of the data was checked using inter class correlation coefficient. For comparing the different histological grades of epithelial dysplasia with the nuclear and cytoplasmic staining, the mean obtained was subjected to one way ANOVA test followed by post hoc test between different groups. The P<0.05 were considered significant.
| » Results|| |
The present study included a total of 30 cases of oral leukoplakia for which immunohistochemical analysis of p53 expression was performed. [Table 1] provides a detailed clinical, histological, and p53 immunoprofile. Immunohistochemical localization of p53 in dysplastic epithelium was found in the nucleus or in cytoplasm or both. Reliability of the data was checked by inter-class correlation coefficient, which was 0.99 for nuclear staining and 0.985 for cytoplasmic staining. In the normal oral mucosa p53 expression was observed in only a few cells of the basal layer [Figure 1]a, while the suprabasal spinous cell layers were devoid of p53 antigen expression. In the present study, the control sections of breast carcinoma [Figure 1]b and oral squamous cell carcinoma [Figure 1]c showed strong p53 expression (++).
|Figure 1: Photomicrograph showing p53 expression (a) in normal oral mucosa - ×100; (b) breast carcinoma - ×100; (c) oral squamous cell carcinoma - ×100; (d) negative staining (-) in dysplasia - ×100; (e) mild dysplasia - ×100; (f) severe dysplasia - ×100|
Click here to view
|Table 1: Profiling of p53 expression in cases with different grades of dysplasia|
Click here to view
It was observed that 21 out of 30 cases (70%) were positive for p53 immunostaining [Table 2]. Among the cases which showed negative staining [Figure 1]d, four were histologically diagnosed mild epithelial dysplasia, three were the moderate dysplasia, and two were severe dysplasia. On the other hand, p53 immunopositivity was observed in six cases of mild dysplasia, seven of moderate dysplasia and eight of severe dysplasia.
Out of the positive cases, p53 staining was weak in 9 cases [Figure 1]e and showed strong intensity in 12 cases [Figure 1]f. The weak p53 staining was high for mild dysplasia as it was observed in all the six cases, while only two out of seven of moderate dysplasia and one out of eight with severe dysplasia showed weak staining [Figure 2]. In cases which showed strong p53 staining seven were severe dysplasia and five were moderate dysplasia. None of the tissue sections that were histologically diagnosed as mild dysplasia showed strong staining for p53. The chi-square test for intensity of different grades of dysplasia gave the likelihood ratio of 15.244, with P<0.05.
|Figure 2: Bar diagram depicting intensity of p53 expression in different grades of dysplasia; Chi square "χ2" test - 11.833; Exact mid P value = .019|
Click here to view
The assessment of p53 distribution in dysplastic epithelium revealed that p53 positivity was confined primarily to the basal cells in mild dysplasia, while three out of seven cases of moderate dysplasia showed basal distribution and remaining four cases showed both basal and suprabasal distribution. The basal as well as suprabasal staining was noted in seven out of eight cases of severe dysplasia and the only other case of severe dysplasia showed basal distribution. The exact P value obtained by the chi-square "χ2" test was 10.619, with highly significant P value (P=0.004) [Figure 3].
|Figure 3: Bar diagram depicting the distribution of p53 in the basal and suprabasal half of dysplastic epithelium; Chi Square "χ 2" test -10.619; Exact P value = 0.004|
Click here to view
Immunohistochemical staining of p53 positive dysplastic cells for intra-cellular localization with reference to its nuclear or cytoplasmic staining was evaluated. In six positive cases of mild dysplasia, the mean number of cells showing nuclear staining was 13.5 ± 6.33, while cytoplasmic staining was seen in 6 ± 3.55 cells. Out of seven positive cases of moderate dysplasia, the mean number of cells with nuclear staining was 33.7 ± 7.13 and those with cytoplasmic staining were 23.2 ± 8.40. Likewise, in eight positive cases of severe dysplasia, the mean number of cells with nuclear staining was 63.6 ± 16.93 and with cytoplasmic staining were 30.4 ± 10.11. It was found that the mean of nuclear and cytoplasmic staining between and within the groups were found to be F = 47.72; P<0. 001 and F = 28.409 P<0.001 respectively [Figure 4]. From these tests, it was evident that there was a very high significance noted between mild dysplasia and severe dysplasia cases.
|Figure 4: Bar diagram showing the mean of intra cellular localization of p53-positive cells in different histological grades of dysplasia; F = 47.72; P<0.001 (Between the groups) and F = 28.409 P <0.001 (Within the group)|
Click here to view
| » Discussion|| |
p53, a tumor suppressor protein, acts as a "molecular brake" to critically regulate the cell cycle. This DNA-binding protein has also been involved in DNA repair and synthesis, cell proliferation, cell differentiation, programmed cell death, and in the maintenance of genomic stability. As p53 protein has been reported to be expressed at high levels in malignant lesions , assessment of its levels in premalignant lesions is significant. , Since majority of OSCCs have the occurrence of leukoplakia in its close vicinity and tobacco being a common risk factor in this multistep and multifocal process,  the analysis of p53 levels in tobacco-associated potentially malignant disorder of the oral cavity through its various histological grades was regarded to be crucial.
In a normal cell, the p53 protein is kept at a low concentration by rapid degradation. In addition, p53 exists in a latent, inactive form.  Several stressful situations including genotoxic DNA damage, hypoxia, and deprivation of growth factors and loss of cell to cell contact can induce the formation of functional p53. Activation of p53 occurs by increasing the p53 protein concentration by enhanced translation or by the transformation of p53 protein from a latent to an active conformation or by the translocation of p53 protein from cytoplasm to the nucleus. 
Our observation, revealing highly significant differences in p53 immunolocalization and staining intensity in severe dysplasia cases more than in mild dysplasia is in agreement with other studies carried out by Girod et al.,  Iwasa M et al. and Kovesi et al. These findings suggest a strong correlation between p53 expression and degree of dysplasia, thus confirming that p53 may be involved in proliferative events as well as in neoplastic transformation. 
Comparison of p53 staining intensity in positive cases revealed that p53 expression was weak in mild dysplasia compared to moderate and severe dysplasia which showed stronger staining intensity. Similar observations have been made by Langdon et al.,  where the intensity was greater with increase in cellular atypia, particularly due to tobacco associated habits. This may be directly related to the activity of p53 which may be increased during the early stages of tumor progression.  The p53 molecule can be further modulated during the advancement of lesion, because of a functional interaction between the p53 molecule and other cellular proteins. The weak intensity observed in two cases of moderate and one case of severe dysplasia can be explained due to the role of other oncogenes like H ras, C-fos, jun family, c-myc, and trophic factors that participate in growth regulation and when inappropriately expressed, generate growth signals that may override the cellular control of p53. 
Distribution of p53 immunoexpression confined to the basal layer in cases of mild dysplasia, as opposed to moderate and severe dysplasias expressed in both the basal and suprabasal staining with increased frequency is in agreement with studies by Kerdpon et al.,  Cruz et al.,  and Nylander et al.  Expression of p53 in suprabasal cells in moderate and severe dysplasia states indicated that the superficial cells of the epithelium were mitotically active resulting in an abnormally proliferative state. This is in contrast to normal mucosa, where it is only the basal cells of the epithelium, which proliferate, differentiate, and mature to form keratinized squames. It has also been pointed out that an increase in p53-positive cells in suprabasal layers of the epithelium in oral premalignant lesions of leukoplakia suggests an imminent potential for aggressive behavior. 
Our observations made with respect to correlation between grading and intracellular localization of p53 suggest that moderate and severely dysplastic leukoplakias have greater potential for malignant transformation than that of mild dysplasia or no dysplasia. These changes could be attributable to the regulation of p53 which is either through enhanced nuclear import or decreased nuclear export or retention.  Binding of p53 with MDM2 is essential for p53 degradation in the cytoplasm by ubiquitination. However, abnormal sequestration of wild-type p53 in cytoplasm, which is known to occur in many human malignancies, may be due to its loss of function as a transcription factor to bring about cell cycle arrest.
Mutations in p53 gene also results in the protein accumulation within the nucleus  and studies suggest that tumorigenesis could result from a defect in the regulation of wild-type p53 nuclear import. , Since the presence of detectable p53 does not necessarily reflect the effect of mutations, no definitive conclusions could be drawn about mutations resulting in cellular proliferation based on immunohistochemistry results alone. However, the mutant form of p53 proteins are known to be more stable, have an extended half life and thus accumulate in higher concentrations as is observed in carcinoma of breast and colon. 
| » Conclusions|| |
Our observations contribute to previous findings that p53 immunoexpression could be used as a specific marker for lesions that are at high risk of malignant transformation. p53 as a prognostic marker may stand as a useful supplement of histopathological assessment in the prognosis of potentially malignant oral lesions. However, further studies with larger sample size using a panel of related molecules are necessary to establish the full potential of p53 as a prognostic marker in potentially malignant oral lesions.
| » References|| |
|1.||Bánóczy J, Csiba A. Occurrence of epithelial dysplasia in Oral leukoplakia. Oral Surg Oral Med Oral Pathol 1976;42:766-74. |
|2.||van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 2009;45:317-23. |
|3.||Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980;8:287-33. |
|4.||Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: A follow-up study of 257 patients. Cancer 1984;53:563-8. |
|5.||Bouquot JE, Whitaker SB. Oral leukoplakia--rationale for diagnosis and prognosis of its clinical subtypes or "phases". Quintessence Int 1994;25:133-40. |
|6.||Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: An overview of the literature. J Oral Pathol Med 2008;37:1-10. |
|7.||Piemonte ED, Lazos JP, Brunotto M. Relationship between chronic trauma of the oral mucosa, oral potentially malignant disorders and oral cancer. J Oral Pathol Med 2010;39:513-7. |
|8.||Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:188-91. |
|9.||Kujan O, Khattab A, Oliver RJ, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. Oral Oncol 2007;43:224-31. |
|10.||Langdon JD, Partridge M. Expression of the tumor suppressor gene p53 in oral cancer. Br J Oral Maxillofac Surg 1992;30:214-20. |
|11.||Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6. |
|12.||Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8. |
|13.||Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:321-9. |
|14.||Cruz I, Napier SS, van der Waal I, Snijders PJ, Walboomers JM, Lamey PJ, et al. Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. J Clin Pathol 2002;55:98-104. |
|15.||Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147:790-8. |
|16.||Mitra S, Sikdar N, Misra C, Gupta S, Paul RR, Roy B, et al. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int J Cancer 2005;117:786-93. |
|17.||Ogden GR, Kiddie RA, Lunny DP, Lane DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992;166:389-94. |
|18.||Kusama K, Okutsu S, Takeda A, Himiya T, Kojima A, Kidokoro Y, et al. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996;178:415-21. |
|19.||Lane D. Awakening angels. Nature 1998;394:616-61. |
|20.||Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-26. |
|21.||Girod SC, Pfeiffer P, Ries J, Pape HD. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1998;36:252-60. |
|22.||Iwasa M, Imamura Y, Noriki S, Nishi Y, Kato H, Fukuda M. Immunohistochemical detection of early-stage carcinogenesis of oral leukoplakia by increased DNA-instability and various malignancy markers. Eur J Histochem 2001;45:333-46. |
|23.||Kövesi G, Szende B. Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia. Oncology 2003;65:331-6. |
|24.||Kerdpon D, Rich IS, Reade PC. Expression of p53 in oral mucosal hyperplasia, dysplasia and squamous cell carcinoma. Oral Dis 1997;3:86-92. |
|25.||Kaur J, Chakravarti N, Mathur M, Srivastava A, Ralhan R. Alterations in expression of retinoid receptor beta and p53 in oral submucous fibrosis. Oral Dis 2004;10:201-6. |
|26.||Studzinski GP. Oncogene growth and the cell cycle: An overview. Cell Tissue Kinet 1989;22:405-24. |
|27.||Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998;184:360-8. |
|28.||Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med. 2000;29:413-25. |
|29.||Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11. |
|30.||Warnakulasuriya KA, Johnson NW. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 1992;21:404-8. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2]
|This article has been cited by|
||Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia
| ||Davide Bartolomeo Gissi,Andrea Gabusi,Achille Tarsitano,Laura Luccarini,Luca Morandi,Lucio Montebugnoli |
| ||Journal of Cranio-Maxillofacial Surgery. 2018; 46(5): 759 |
|[Pubmed] | [DOI]|
||Sextuple Tumors in Head and Neck Area: Evidence of Field Cancerization
| ||Carla Bento Nelem-Colturato,Patrícia Maluf Cury,Thiago Machado Pereira,Isabelle Silva Cosso,Kellin Pivato,Luiz Evaristo Ricci Volpato,Alvaro Henrique Borges |
| ||Case Reports in Pathology. 2018; 2018: 1 |
|[Pubmed] | [DOI]|
||Predictive Role of p53 Protein as a Single Marker or Associated with ki67 Antigen in Oral Leukoplakia: A Retrospective Longitudinal Study
| ||Davide B Gissi,Andrea Gabusi,Dora Servidio,Fabio Cervellati,Lucio Montebugnoli |
| ||The Open Dentistry Journal. 2015; 9(1): 41 |
|[Pubmed] | [DOI]|
||Molecular Pathology Signatures in Predicting Malignant Potentiality of Dysplastic Oral Pre-cancers
| ||Satarupa Banerjee,Jyotirmoy Chatterjee |
| ||Springer Science Reviews. 2015; 3(2): 127 |
|[Pubmed] | [DOI]|